Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Lindbrook Capital LLC

Lindbrook Capital LLC grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 40.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,065 shares of the company’s stock after purchasing an additional 1,174 shares during the period. Lindbrook Capital LLC’s holdings in Takeda Pharmaceutical were worth $58,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. XY Capital Ltd boosted its stake in Takeda Pharmaceutical by 432.5% during the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock valued at $10,919,000 after buying an additional 621,440 shares in the last quarter. FMR LLC boosted its stake in Takeda Pharmaceutical by 4.7% during the third quarter. FMR LLC now owns 2,593,350 shares of the company’s stock valued at $40,119,000 after buying an additional 115,947 shares in the last quarter. Brandes Investment Partners LP boosted its stake in Takeda Pharmaceutical by 2.1% during the third quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock valued at $27,877,000 after buying an additional 36,717 shares in the last quarter. Citigroup Inc. boosted its stake in Takeda Pharmaceutical by 5.6% during the third quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock valued at $896,000 after buying an additional 3,089 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in Takeda Pharmaceutical during the third quarter valued at about $2,105,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 1.2 %

Shares of TAK stock opened at $13.07 on Friday. The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a fifty-two week low of $13.05 and a fifty-two week high of $17.11. The stock has a market capitalization of $41.35 billion, a P/E ratio of 19.80, a P/E/G ratio of 3.02 and a beta of 0.53. The stock has a 50-day simple moving average of $14.09 and a 200 day simple moving average of $14.21.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The business had revenue of $7.52 billion during the quarter. On average, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.